Cellular blood components may result in the transmission of CMV to groups of patients at risk. Practice in many EU countries is to use leucodepleted blood components to avoid this risk. In some countries the use of blood components that test negative for CMV antibody is recommended for patients at special risk of CMV infection (PMID 11149975).